Correlation Between Syndax Pharmaceuticals and Werewolf Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Syndax Pharmaceuticals and Werewolf Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Syndax Pharmaceuticals and Werewolf Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Syndax Pharmaceuticals and Werewolf Therapeutics, you can compare the effects of market volatilities on Syndax Pharmaceuticals and Werewolf Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Syndax Pharmaceuticals with a short position of Werewolf Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Syndax Pharmaceuticals and Werewolf Therapeutics.

Diversification Opportunities for Syndax Pharmaceuticals and Werewolf Therapeutics

0.49
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Syndax and Werewolf is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and Werewolf Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Werewolf Therapeutics and Syndax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Syndax Pharmaceuticals are associated (or correlated) with Werewolf Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Werewolf Therapeutics has no effect on the direction of Syndax Pharmaceuticals i.e., Syndax Pharmaceuticals and Werewolf Therapeutics go up and down completely randomly.

Pair Corralation between Syndax Pharmaceuticals and Werewolf Therapeutics

Given the investment horizon of 90 days Syndax Pharmaceuticals is expected to under-perform the Werewolf Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Syndax Pharmaceuticals is 1.78 times less risky than Werewolf Therapeutics. The stock trades about -0.07 of its potential returns per unit of risk. The Werewolf Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  214.00  in Werewolf Therapeutics on September 16, 2024 and sell it today you would lose (49.00) from holding Werewolf Therapeutics or give up 22.9% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Syndax Pharmaceuticals  vs.  Werewolf Therapeutics

 Performance 
       Timeline  
Syndax Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Werewolf Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Werewolf Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest inconsistent performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.

Syndax Pharmaceuticals and Werewolf Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Syndax Pharmaceuticals and Werewolf Therapeutics

The main advantage of trading using opposite Syndax Pharmaceuticals and Werewolf Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Syndax Pharmaceuticals position performs unexpectedly, Werewolf Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Werewolf Therapeutics will offset losses from the drop in Werewolf Therapeutics' long position.
The idea behind Syndax Pharmaceuticals and Werewolf Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios